In vitro studies have shown that miR-22 is significantly downregulated in malignant CTCL T cell lines (MyLa2059), and Jak3/STAT pathway-mediated inhibition of miR-22 may play a key role in CTCL pathogenesis and progression (39). This evidence concerns the gene JAK3 and primary cutaneous T-cell non-Hodgkin lymphoma.